EMA's CHMP recommends Zaltrap for colorectal cancer
This article was originally published in Scrip
Executive Summary
Sanofi and Regeneron Pharmaceuticals have received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Zaltrap (aflibercept) for previously untreated metastatic colorectal cancer (mCRC). A final decision is expected from the European Commission in the first quarter of 2013.